CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patients

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs